These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19408838)

  • 41. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy.
    Liang CC; Liu CH; Lin YL; Liu CJ; Chiang BL; Kao JH
    J Med Virol; 2011 Jul; 83(7):1212-20. PubMed ID: 21567425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C (PRACTICE).
    Bourgeois S; Deltenre P; Delwaide J; Henrion J; Adler M; Langlet P; Mulkay JP; Nevens F; Brixko C; Moreno C
    Acta Gastroenterol Belg; 2014 Dec; 77(4):393-400. PubMed ID: 25682628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.
    Mangia A; Bandiera F; Montalto G; Mottola L; Piazzolla V; Minerva N; Pellicelli A; Ricci GL; Cela M; Carretta V; Scotto G; Bacca D; Annicchiarico B; Romano M; Russello M; Barbarini G; Agostinacchio E; Andriulli A
    J Hepatol; 2010 Dec; 53(6):1000-5. PubMed ID: 20843575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
    Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
    Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapy of chronic hepatitis C--virologic response monitoring].
    Kuljić-Kapulica N; Jovanović D; Savić D; Ristanović E; Nozić D; Rajić R
    Vojnosanit Pregl; 2010 Nov; 67(11):923-7. PubMed ID: 21268927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
    Nagoshi S; Koshima Y; Nakamura I; Funyu J; Sekine C; Harada Y; Nishikawa K; Yoshida T; Matsui A; Sotome N; Toshima K; Takegoshi S; Shiomi M; Tanaka M; Saito A; Fujiwara K; Mochida S
    Intern Med; 2012; 51(1):9-15. PubMed ID: 22214617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
    Bortoletto G; Scribano L; Realdon S; Marcolongo M; Mirandola S; Franceschini L; Bonisegna S; Noventa F; Plebani M; Martines D; Alberti A
    J Viral Hepat; 2010 Jul; 17(7):475-80. PubMed ID: 19878535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].
    Urbánek P; Subhanová I; Janousová E; Dusek L; Marecek Z; Brůha R; Petrtýl J; Brodanová M
    Vnitr Lek; 2009 May; 55(5):474-9. PubMed ID: 19514613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
    Hotho DM; de Bruijne J; Spaan M; Treitel MA; Boonstra A; de Knegt RJ; Janssen HL; Reesink HW
    J Viral Hepat; 2013 Apr; 20(4):e78-81. PubMed ID: 23490393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy.
    Ohkoshi S; Yamagiwa S; Yano M; Takahashi H; Aoki YH; Waguri N; Igarashi K; Sugitani S; Takahashi T; Ishikawa T; Kamimura T; Wakabayashi H; Watanabe T; Matsuda Y; Aoyagi Y
    Hepatogastroenterology; 2011; 58(107-108):965-70. PubMed ID: 21830425
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.
    Mangia A; Dalgard O; Minerva N; Verbaan H; Bacca D; Ring-Larsen H; Copetti M; Carretta V; Piazzolla V; Cozzolongo R; Mottola L; Andriulli A
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1346-53. PubMed ID: 20222909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
    Macías J; del Valle J; Rivero A; Mira JA; Camacho A; Merchante N; Pérez-Camacho I; Neukam K; Rivero-Juárez A; Mata R; Torre-Cisneros J; Pineda JA;
    J Antimicrob Chemother; 2010 Oct; 65(10):2204-11. PubMed ID: 20656678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study on effect of intensive treatment for refractory chronic hepatitis C patients].
    Li MH; Zhang YL; Zhang L; Shen G; Qiu GH; Lu Y; Zhuang LW; Gao YJ; Yang M; Wu Y; Xie Y; Cheng J; Xu D
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Oct; 26(5):374-8. PubMed ID: 23550318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
    Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
    Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.
    Iacobellis A; Siciliano M; Annicchiarico BE; Valvano MR; Niro GA; Accadia L; Caruso N; Bombardieri G; Andriulli A
    Aliment Pharmacol Ther; 2009 Jul; 30(2):146-53. PubMed ID: 19392868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J
    Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population.
    Dahlan Y; Ather HM; Al-ahmadi M; Batwa F; Al-hamoudi W
    World J Gastroenterol; 2009 Sep; 15(35):4429-33. PubMed ID: 19764095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users].
    Ruzić M; Milotka F; Klasnja B; Pobor M; Svarc D; Jovelic A; Fabri I
    Srp Arh Celok Lek; 2010; 138(1-2):43-9. PubMed ID: 20425908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.